{
  "schemaVersion": 2,
  "eyebrow": "Thrombosis",
  "title": "VTE Anticoagulation Duration",
  "summary": "Select anticoagulation duration after venous thromboembolism by classifying the provoking context, estimating recurrence and bleeding risk, and reassessing persistent risks. Most transiently provoked events require 3 months; unprovoked, recurrent, and active cancer-associated VTE commonly warrant extended therapy.",
  "seoDescription": "Physician guide to selecting anticoagulation duration after DVT or PE, including provoked, unprovoked, recurrent, cancer-associated VTE, and reduced-dose DOAC options.",
  "clinicalQuestion": "How long should anticoagulation continue after DVT or pulmonary embolism?",
  "specialty": "Hematology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "venous thromboembolism",
    "DVT anticoagulation duration",
    "pulmonary embolism duration",
    "extended anticoagulation",
    "unprovoked VTE",
    "cancer-associated thrombosis",
    "DOAC"
  ],
  "keyTakeaways": [
    "Treat VTE provoked by a transient risk factor with a limited 3-month anticoagulation course unless a separate persistent indication changes the balance. [2]",
    "After unprovoked PE, stopping anticoagulation carries an estimated 10% recurrence risk in the first year and approximately 5% per year thereafter; reassess bleeding risk and patient values when considering extended therapy. [14]",
    "For active cancer-associated VTE, treat for at least 3–6 months and generally continue while cancer remains active, with regular reassessment. [5][7]",
    "Apixaban 2.5 mg twice daily and rivaroxaban 10 mg once daily are FDA-approved reduced-intensity options for extended VTE treatment after the initial treatment phase. [15][20]",
    "Do not use a fixed treatment duration without revisiting recurrence drivers, bleeding risk, renal function, hepatic disease, drug interactions, adherence, and patient preferences. [14][22]"
  ],
  "sections": [
    {
      "id": "make-the-duration-decision",
      "eyebrow": "Initial decision",
      "heading": "Classify the index VTE before choosing duration",
      "intro": "Duration depends principally on whether the provoking risk has resolved, persists, or is absent.",
      "paragraphs": [
        "At completion of the initial treatment phase, classify the event as provoked by a transient risk factor, associated with active cancer, or unprovoked. This classification estimates recurrence risk after treatment is stopped and determines whether the default plan is finite treatment or extended anticoagulation. A first unprovoked VTE has an estimated recurrence risk of about 10% in the first year after anticoagulation is discontinued and about 5% annually thereafter. [14]",
        "Use “transiently provoked” only when the risk factor was time-limited and has resolved. CHEST describes examples of minor transient factors including an acute illness with bed confinement for at least 3 days and leg injury with reduced mobility for at least 3 days. Patients with minor transient factors are the group in whom recurrence risk and bleeding risk from extended therapy are most closely balanced; the decision should be preference-sensitive rather than automatic. [12]",
        "Before committing to indefinite therapy, document the estimated recurrence hazard if treatment stops and the patient-specific bleeding hazard if treatment continues. High bleeding risk can outweigh the benefit of extended therapy even after unprovoked PE or with persistent risk factors; regular reassessment is required because both risks can change over time. [14]"
      ],
      "bullets": [
        "Transient provoking factor resolved: plan a finite course, usually 3 months. [2]",
        "No transient provoking factor or a continuing risk driver: discuss extended anticoagulation after the initial treatment phase. [12][14]",
        "Active cancer: continue beyond the initial 3–6 months while cancer is active unless bleeding risk or goals of care favor stopping. [5][7]"
      ],
      "subsections": [],
      "table": {
        "caption": "Duration framework after objectively confirmed DVT or PE. [2][5][7][12][14]",
        "columns": [
          "Index-event context",
          "Default duration approach",
          "Decision modifier at follow-up"
        ],
        "rows": [
          [
            "VTE provoked by a resolved transient risk factor",
            "Limited 3-month course. [2]",
            "Do not extend solely because treatment has been tolerated; identify a persistent indication if continuing. [2]"
          ],
          [
            "VTE with a minor transient risk factor",
            "Finite therapy is generally favored, but the recurrence-versus-bleeding balance is close. [12]",
            "Use shared decision-making; some guidelines differ on extended therapy for this group. [12]"
          ],
          [
            "First unprovoked VTE",
            "Evaluate for extended therapy after initial treatment. [14]",
            "Stopping anticoagulation after unprovoked PE is associated with approximately 10% recurrence in year 1 and 5% per year thereafter. [14]"
          ],
          [
            "Active cancer-associated VTE",
            "Treat for at least 3–6 months and generally continue while cancer remains active. [5][7]",
            "Reassess cancer activity, recurrence, bleeding, and treatment changes at regular intervals. [5]"
          ]
        ]
      }
    },
    {
      "id": "finite-treatment",
      "eyebrow": "Finite therapy",
      "heading": "When 3 months is sufficient for provoked VTE",
      "intro": "A resolved transient trigger is the principal reason to stop after primary treatment.",
      "paragraphs": [
        "For provoked VTE, guidelines have recommended a limited 3-month course for more than a decade. [2] This is a duration decision, not a mandate to use a particular anticoagulant; select the acute and primary-treatment regimen according to the patient’s renal function, hepatic function, drug interactions, bleeding risk, and access.",
        "Do not extend anticoagulation merely because residual symptoms persist, because a follow-up ultrasound shows residual venous abnormality, or because the index event was a PE rather than DVT without first establishing that the patient has a persistent recurrence driver. Evidence cited in recurrence literature describes residual vein thrombosis as a studied stratification approach, but duration decisions should remain anchored to the provoking context and net clinical benefit. [9][12]",
        "At the planned stop date, verify that the provoking condition has resolved and that there is no newly recognized active cancer, recurrent VTE, or other persistent thrombotic driver. Review interval bleeding, adherence, concomitant antiplatelet or anti-inflammatory drugs, renal and hepatic function, and the patient’s priorities before either discontinuing or converting to an extended regimen. Anticoagulation-management systems can specifically monitor adherence, interactions, renal and hepatic function, and bleeding or thrombotic events. [22]"
      ],
      "bullets": [
        "Record the provoking factor and its resolution in the anticoagulation stop plan. [2][12]",
        "If the clinical history suggests a minor rather than major transient factor, explicitly discuss the less certain net benefit of extension. [12]",
        "Give return precautions for new unilateral limb symptoms, pleuritic chest pain, dyspnea, syncope, or hemoptysis because recurrence remains possible after treatment cessation. [8]"
      ],
      "subsections": [],
      "table": {
        "caption": "",
        "columns": [],
        "rows": []
      }
    },
    {
      "id": "extended-treatment",
      "eyebrow": "Secondary prevention",
      "heading": "Extended therapy for unprovoked or persistent-risk VTE",
      "intro": "Extended anticoagulation reduces recurrence while exposure continues but requires periodic net-benefit reassessment.",
      "paragraphs": [
        "For a first unprovoked PE, extended anticoagulation is generally considered because recurrence after discontinuation is high: approximately 10% in the first year and 5% per year thereafter. [14] This decision is strongest when bleeding risk is low or moderate; where bleeding risk is high, guidance cited for unprovoked PE and persistent risk factors recommends against extended therapy. [14]",
        "If a patient with first unprovoked VTE is considering discontinuation, recurrence-prediction tools may help structure counseling rather than replace clinical judgment. The Vienna Prediction Model incorporates sex, thrombus location, and D-dimer; in the cited model, D-dimer measured 3 weeks after anticoagulation was used with sex and location to stratify recurrence risk. [4] D-dimer has also been incorporated into HERDOO2, DASH, and DAMOVES approaches. [13] These tools estimate recurrence risk, not bleeding risk, and their performance may not fully translate to patients receiving DOACs. [14]",
        "For long-term secondary prevention, reduced-intensity factor Xa inhibitor regimens offer an option after completion of initial VTE treatment: apixaban 2.5 mg orally twice daily or rivaroxaban 10 mg orally once daily. Both regimens are FDA-approved for extended-duration VTE treatment; they have demonstrated efficacy comparable with full-intensity extended therapy with numerically lower composite major and clinically relevant nonmajor bleeding rates. [15] Apixaban 2.5 mg twice daily after 6 months of initial DVT treatment has been reported to reduce recurrence risk. [20]",
        "Use full-intensity versus reduced-intensity extended therapy as an individualized choice rather than a reflex dose reduction. Reassess recurrence risk, prior recurrence on therapy, active cancer status, renal and hepatic function, drug interactions, and bleeding history. Apixaban has approximately 27% renal elimination, whereas dabigatran has approximately 80%; renal impairment prolongs DOAC half-life and can alter both bleeding risk and periprocedural planning. [18][23]"
      ],
      "bullets": [
        "Apixaban: acute DVT/PE regimen is 10 mg orally twice daily for 7 days, then 5 mg orally twice daily; after the initial treatment phase, 2.5 mg twice daily is an extended-treatment option. [18][20]",
        "Rivaroxaban: 10 mg orally once daily is an FDA-approved reduced-intensity extended-treatment option. [15]",
        "Avoid rivaroxaban in acute renal failure, CrCl below 15 mL/min, moderate-to-severe hepatic impairment, or liver disease with coagulopathy. [20]",
        "For patients declining or unable to continue anticoagulation after unprovoked VTE, aspirin 100 mg daily was studied after 6–18 months of anticoagulation, but it is not a therapeutic anticoagulant substitute. [9]"
      ],
      "subsections": [
        {
          "heading": "D-dimer-directed discontinuation",
          "paragraphs": [
            "Order D-dimer only when its result will alter a close decision about stopping extended therapy after a first unprovoked VTE. In the Vienna model, serial D-dimer values can update estimated recurrence risk, and an abnormal D-dimer after anticoagulation cessation has been associated with recurrence risk. [4][13] Do not interpret a D-dimer result in isolation from sex, event location, provoking context, and bleeding risk. [4][14]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Extended-treatment options after the initial VTE treatment phase. [15][18][20]",
        "columns": [
          "Regimen",
          "Supported extended-treatment dose",
          "Key use consideration"
        ],
        "rows": [
          [
            "Apixaban",
            "2.5 mg orally twice daily after initial treatment. [15][20]",
            "Standard acute DVT/PE treatment begins with 10 mg twice daily for 7 days, then 5 mg twice daily. [18]"
          ],
          [
            "Rivaroxaban",
            "10 mg orally once daily. [15]",
            "Avoid with acute renal failure, CrCl <15 mL/min, moderate-to-severe hepatic impairment, or liver disease with coagulopathy. [20]"
          ],
          [
            "Dabigatran",
            "No reduced-intensity extended dose specified here.",
            "Renal elimination is approximately 80%, making renal function particularly relevant. [18]"
          ]
        ]
      }
    },
    {
      "id": "cancer-associated-vte",
      "eyebrow": "Cancer-associated thrombosis",
      "heading": "Continue anticoagulation while cancer is active",
      "intro": "Cancer activity is a continuing recurrence driver and should be reassessed, not treated as a static label.",
      "paragraphs": [
        "For cancer-associated VTE, provide therapeutic anticoagulation for at least 3–6 months and generally continue as long as cancer remains active. [5][7] At each reassessment, determine whether malignancy remains active and whether ongoing anticancer treatment, recurrent VTE, bleeding, or changing goals of care shifts the net benefit of continuing therapy. [5]",
        "Stopping anticoagulation in cancer-associated thrombosis carries substantial recurrence risk. In a systematic review and meta-analysis, cumulative recurrence after discontinuation was 28.3% at 1 year, 31.1% at 2 years, and 35.0% at 5 years; recurrence was especially high in the first months after stopping. [5] These estimates support caution when considering discontinuation in a patient with ongoing active cancer.",
        "After 6 months, do not automatically stop or automatically continue without a documented review. Continued anticoagulation beyond 6 months is justified when cancer remains active or VTE recurred during the first 6 months; otherwise, individualize according to recurrence risk, bleeding risk, cancer trajectory, treatment burden, and patient priorities. [5]"
      ],
      "bullets": [
        "Minimum treatment: 3–6 months of therapeutic anticoagulation. [5][7]",
        "Usual continuation criterion: active cancer. [5]",
        "Strong reason to continue beyond 6 months: recurrent VTE during the initial 6 months. [5]",
        "Reassess periodically for both recurrence and major bleeding, which are influenced by cancer activity. [5]"
      ],
      "subsections": [],
      "table": {
        "caption": "",
        "columns": [],
        "rows": []
      }
    },
    {
      "id": "monitoring-and-interruption",
      "eyebrow": "Longitudinal safety",
      "heading": "Monitor extended therapy and manage procedures without unnecessary bridging",
      "intro": "Extended treatment requires surveillance for changing exposure, bleeding, and interruption needs.",
      "paragraphs": [
        "At every renewal or follow-up visit, confirm the indication and intended duration; ask about missed doses, recurrent VTE symptoms, clinically relevant bleeding, new antiplatelet or interacting medications, renal impairment, hepatic impairment, and upcoming procedures. Structured anticoagulation services can monitor adherence, interactions, renal and hepatic function, and thrombotic or bleeding events. [22]",
        "For elective procedures, use a standardized, pharmacokinetic interruption plan based on procedure bleeding risk, renal function, and the DOAC. Routine preoperative DOAC drug-level testing is not recommended for elective procedures, and heparin bridging is generally unnecessary because DOAC interruption intervals are short. [17][22]",
        "For low-to-moderate bleeding-risk procedures, omit the DOAC dose 1 day before the procedure, approximately 30–36 hours. For higher-risk surgery, hold apixaban, edoxaban, or rivaroxaban for 2 days before surgery, approximately 60–68 hours; hold dabigatran for 2–4 days according to renal function. [17] For neuraxial procedures, discontinue oral factor Xa inhibitors for 3 days and dabigatran for 4 days. [17]",
        "Resume DOAC therapy according to procedural bleeding risk and achieved hemostasis, typically 1–3 days post-procedure and not before 24 hours. [17] In emergency surgery, major bleeding risk is reported at 17%–23% and arterial thromboembolism at 7%–16%; prothrombin complex concentrate can reverse all DOACs, idarucizumab reverses dabigatran, and andexanet alfa reverses oral factor Xa inhibitors. [17]"
      ],
      "bullets": [
        "Do not bridge DOAC interruption with heparin routinely. [17][22]",
        "Measure a DOAC level selectively in urgent settings when it will guide reversal, not routinely before elective procedures. [22]",
        "Escalate urgent bleeding or emergency-procedure management to a protocolized reversal pathway; reversal-agent choice depends on the specific DOAC. [17]"
      ],
      "subsections": [],
      "table": {
        "caption": "Elective DOAC interruption and resumption framework. [17][22]",
        "columns": [
          "Clinical setting",
          "Interruption approach",
          "Resumption or escalation"
        ],
        "rows": [
          [
            "Low-to-moderate bleeding-risk procedure",
            "Skip DOAC dose 1 day before; approximately 30–36 hours without drug. [17]",
            "Resume after hemostasis, not before 24 hours. [17]"
          ],
          [
            "Higher-risk surgery",
            "Hold apixaban, edoxaban, or rivaroxaban for 2 days; hold dabigatran 2–4 days based on renal function. [17]",
            "Resume 1–3 days post-procedure based on bleeding risk and hemostasis. [17]"
          ],
          [
            "Neuraxial procedure",
            "Hold oral factor Xa inhibitors for 3 days and dabigatran for 4 days. [17]",
            "Use procedural and anesthetic hemostasis requirements to determine restart. [17]"
          ],
          [
            "Urgent surgery or major bleeding",
            "Do not delay protocolized assessment for routine drug-level testing. [22]",
            "Consider PCC for any DOAC; idarucizumab for dabigatran or andexanet alfa for factor Xa inhibitors. [17]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "Should anticoagulation be stopped after 3 months for a first unprovoked PE?",
      "answer": "Usually not automatically. After anticoagulation is stopped for unprovoked PE, recurrence is estimated at 10% in the first year and about 5% annually thereafter. Consider extended therapy unless bleeding risk, treatment burden, or patient preferences favor discontinuation. [14]"
    },
    {
      "question": "Can a reduced-dose DOAC be used indefinitely after VTE?",
      "answer": "After the initial treatment phase, apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily are FDA-approved extended-treatment regimens. Continue periodic reassessment of recurrence risk, bleeding, renal and hepatic function, and adherence. [15][22]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Standardized Management of Direct Oral Anticoagulants",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2830032",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 2,
      "title": "Length of Anticoagulation in Provoked Venous Thromboembolism",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/JAHA.122.025471",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 3,
      "title": "Optimal Duration of Anticoagulation After Venous Thromboembolism",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/circulationaha.110.970822",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 4,
      "title": "d‐Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/jaha.113.000467",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 5,
      "title": "The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2589537023003711",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 6,
      "title": "Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0049384815001048",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 7,
      "title": "Extended anticoagulation treatment for cancer‐associated ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1538783622000629",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 8,
      "title": "Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1538783622004792",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 9,
      "title": "Prevention of recurrent deep-vein thrombosis : Vascular Investigation and Therapy",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/vith/fulltext/2019/02010/prevention_of_recurrent_deep_vein_thrombosis.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 10,
      "title": "Versus Extended‐Dose Anticoagulation for Venous ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/ejh.70142?af=R",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 11,
      "title": "Extended anticoagulation for unprovoked venous thromboembolism",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/rth2.12121",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 12,
      "title": "Antithrombotic Therapy for VTE Disease - CHEST Journal",
      "detail": "journal.chestnet.org",
      "url": "https://journal.chestnet.org/article/S0012-3692(21)01506-3/fulltext",
      "authors": "journal.chestnet.org",
      "host": "journal.chestnet.org"
    },
    {
      "number": 13,
      "title": "D-dimer: Well beyond diagnosis! - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343641",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 14,
      "title": "Duration of Anticoagulation Post-PE: Things to Consider",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2019/03/22/07/45/duration-of-anticoagulation-post-pe",
      "authors": "www.acc.org",
      "host": "www.acc.org"
    },
    {
      "number": 15,
      "title": "Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2022/10/01/01/42/peripheral-matters-dose-reduced-direct-oral-anticoagulants-practical-considerations",
      "authors": "www.acc.org",
      "host": "www.acc.org"
    },
    {
      "number": 16,
      "title": "[PDF] Protocol Phase II/III template - Clinical Trials",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/49/NCT03196349/Prot_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov"
    },
    {
      "number": 17,
      "title": "Perioperative Management of DOACs: Key Points",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2024/08/15/15/36/perioperative-management-of",
      "authors": "www.acc.org",
      "host": "www.acc.org"
    },
    {
      "number": 18,
      "title": "Apixaban - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK507910",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "2025 Guidelines for direct oral anticoagulants: a practical guidance ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12240022",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5156547",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "[PDF] Protocol 854199 - ClinicalTrials.gov",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/10/NCT06243510/Prot_SAP_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov"
    },
    {
      "number": 22,
      "title": "Anticoagulation Safety - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK519025",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Initiating and Managing Patients with Venous Thromboembolism on ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5334484",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "Perioperative management of apixaban in patients with advanced CKD undergoing a planned invasive procedure",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10847030",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Standardized Management of Direct Oral Anticoagulants",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2830032",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "A standardized DOAC interruption protocol was used based on DOAC half-lives and elimination … venous thromboembolism as secondary outcomes.",
      "score": 0.51325434
    },
    {
      "number": 2,
      "title": "Length of Anticoagulation in Provoked Venous Thromboembolism",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/JAHA.122.025471",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "For more than a decade, guidelines have recommended a limited 3 months of anticoagulation for the treatment of provoked venous thromboembolism",
      "score": 0.758958
    },
    {
      "number": 3,
      "title": "Optimal Duration of Anticoagulation After Venous Thromboembolism",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/circulationaha.110.970822",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "The consensus is that these patients should continue anticoagulation for as long as their cancer is active. Their risk of recurrence after",
      "score": 0.57437146
    },
    {
      "number": 4,
      "title": "d‐Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/jaha.113.000467",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "d‐Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model | Journal of the American Heart Association. Patients with unprovoked venous thromboembolism (VTE) can be stratified according to their recurrence risk based on their sex, the VTE loca",
      "score": 0.6897432090517741
    },
    {
      "number": 5,
      "title": "The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2589537023003711",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Open access\n\n## Summary\n\n### Background\n\nThe optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3–6 months and to continue anticoagulant therapy for as long as the cancer is ac",
      "score": 0.7982658
    },
    {
      "number": 6,
      "title": "Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0049384815001048",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Over 1.8 adults per 1000 develop acute venous thromboembolism (VTE) annually . International guidelines recommend initial parenteral anticoagulation plus an oral vitamin-K antagonist (VKA) for ≥3 months . While highly effective in reducing the risk of deep-vein thrombosis (DVT) and pulmonary embolis",
      "score": 0.77446437
    },
    {
      "number": 7,
      "title": "Extended anticoagulation treatment for cancer‐associated ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1538783622000629",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Patients with cancer‐associated venous thromboembolism (VTE) are recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months.",
      "score": 0.7487387
    },
    {
      "number": 8,
      "title": "Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1538783622004792",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### Objectives\n\nTo determine the incidence of recurrent VTE during extended anticoagulation of up to 5 years in patients with a first unprovoked VTE.\n\n### Methods\n\nMEDLINE, EMBASE, and the Cochrane CENTRAL were searched to identify randomized trials and prospective cohort studies reporting recurrent",
      "score": 0.7286136
    },
    {
      "number": 9,
      "title": "Prevention of recurrent deep-vein thrombosis : Vascular Investigation and Therapy",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/vith/fulltext/2019/02010/prevention_of_recurrent_deep_vein_thrombosis.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Title: Prevention of recurrent deep-vein thrombosis : Vascular Investigation and Therapy\nIn the first study (WARFASA),[3] 402 patients who had completed 6–18 months of oral anticoagulant treatment for a first unprovoked DVT were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years. In ",
      "score": 0.6924055186885478
    },
    {
      "number": 10,
      "title": "Versus Extended‐Dose Anticoagulation for Venous ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/ejh.70142?af=R",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "Feb 22, 2026 — Extended-duration anticoagulation reduces recurrent venous thromboembolism (VTE) in cancer and non-cancer patients.",
      "score": 0.588062
    },
    {
      "number": 11,
      "title": "Extended anticoagulation for unprovoked venous thromboembolism",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/rth2.12121",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "This review article summarizes the evidence available for Vitamin-K antagonists (VKAs) and direct oral anticoagulants (DOACs) for extended",
      "score": 0.45653152
    },
    {
      "number": 12,
      "title": "Antithrombotic Therapy for VTE Disease - CHEST Journal",
      "detail": "journal.chestnet.org",
      "url": "https://journal.chestnet.org/article/S0012-3692(21)01506-3/fulltext",
      "authors": "journal.chestnet.org",
      "host": "journal.chestnet.org",
      "snippet": "205.\n\nIorio, A. ∙ Kearon, C. ∙ Filippucci, E. ...\n\nRisk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review\n\n_Arch Intern Med._ 2010; 170(19):1710-1716\n\nCrossref\n\nScopus (123)\n\nPubMed\n\nGoogle Scholar\n\n; and (3) unprovoked",
      "score": 0.6641271
    },
    {
      "number": 13,
      "title": "D-dimer: Well beyond diagnosis! - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343641",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Title: D-dimer: Well beyond diagnosis! - PMC\nAn official website of the United States government. A **.gov** website belongs to an official government organization in the United States. A **lock** (  ) or **https://** means you've safely connected to the .gov website. Find articles by H Robert-Ebadi",
      "score": 0.8180467853040354
    },
    {
      "number": 14,
      "title": "Duration of Anticoagulation Post-PE: Things to Consider",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2019/03/22/07/45/duration-of-anticoagulation-post-pe",
      "authors": "www.acc.org",
      "host": "www.acc.org",
      "snippet": "In those with unprovoked PE who elect to stop indefinite anticoagulation, the risk for recurrent VTE is 10% in the first year after stopping anticoagulation and 5% per year after.2 Although indefinite treatment is recommended in these patients, it is important to reassess the risks and benefits of o",
      "score": 0.7761911306835018
    },
    {
      "number": 15,
      "title": "Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2022/10/01/01/42/peripheral-matters-dose-reduced-direct-oral-anticoagulants-practical-considerations",
      "authors": "www.acc.org",
      "host": "www.acc.org",
      "snippet": "Extended-Duration Treatment of VTE. Apixaban 2.5 mg twice daily12 and rivaroxaban 10 mg once daily,13 as low-intensity DOACs, have been demonstrated to be as effective as the full-intensity DOAC therapy for the extended-duration treatment of VTE, with numerically lower rates of the composite major a",
      "score": 0.7500592
    },
    {
      "number": 16,
      "title": "[PDF] Protocol Phase II/III template - Clinical Trials",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/49/NCT03196349/Prot_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov",
      "snippet": "and apixaban are two Factor Xa inhibitors that are at least as effective and safe as warfarin for treatment of acute VTE (Einstein Investigators 2010; Buller 2012; Agnelli 2013a). Each DOAC has also been compared to placebo for extended anticoagulation in patients with VTE, demonstrating significant",
      "score": 0.7045877
    },
    {
      "number": 17,
      "title": "Perioperative Management of DOACs: Key Points",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2024/08/15/15/36/perioperative-management-of",
      "authors": "www.acc.org",
      "host": "www.acc.org",
      "snippet": "1. DOACs, including apixaban, dabigatran, edoxaban, and rivaroxaban, are the leading oral anticoagulants for common thromboembolic conditions, including atrial fibrillation and venous thromboembolism.\n2. Elimination half-lives for the oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are 8",
      "score": 0.70336664
    },
    {
      "number": 18,
      "title": "Apixaban - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK507910",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Elimination:Apixaban undergoes elimination via both urine and feces and has an apparent half-life of 12 hours following oral administration. Among the DOACs, apixaban exhibits 27% renal elimination, and dabigatran demonstrates predominant renal excretion at 80%. Rivaroxaban and edoxaban also undergo",
      "score": 0.7009158
    },
    {
      "number": 19,
      "title": "2025 Guidelines for direct oral anticoagulants: a practical guidance ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12240022",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "The Perioperative Anticoagulation for Use in Surgery Evaluation (PAUSE) study was a pragmatic multicentre prospective management study of periprocedural management involving 3007 patients with AF taking apixaban, rivaroxaban or dabigatran, where a standard protocol of interruption and resumption was",
      "score": 0.6999322
    },
    {
      "number": 20,
      "title": "Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5156547",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "#### Side effects and contraindications\n\nFor each category of treatment (nonvalvular AF, thromboprophylaxis following orthopedic surgery, and protection against recurrent DVT or PE), there are specific guidelines for how dosages should be modified within the context of renal impairment as mentioned ",
      "score": 0.6778372
    },
    {
      "number": 21,
      "title": "[PDF] Protocol 854199 - ClinicalTrials.gov",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/10/NCT06243510/Prot_SAP_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov",
      "snippet": "(0% vs 3.1%) following the switch, as well as fewer compliance “events” (0% with apixaban vs 33.5% with enoxaparin).26 Notably, this was not a randomized study, not all patients who were discharged on prophylaxis had undergone RC, and not all patients who underwent RC were discharged on prophylaxis;",
      "score": 0.57236487
    },
    {
      "number": 22,
      "title": "Anticoagulation Safety - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK519025",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Periprocedural Management\n\nPeriprocedural management of DOACs should follow a standardized, pharmacokinetic-based approach guided by procedural bleeding risk, renal function, and the specific agent. Results from the PAUSE study supported simple interruption strategies without heparin bridging or rou",
      "score": 0.55796635
    },
    {
      "number": 23,
      "title": "Initiating and Managing Patients with Venous Thromboembolism on ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5334484",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "However, renal function is important to consider, as renal impairment leads to prolonged DOAC half-life and the need to discontinue the DOAC even earlier before",
      "score": 0.5473921
    },
    {
      "number": 24,
      "title": "Perioperative management of apixaban in patients with advanced CKD undergoing a planned invasive procedure",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10847030",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "## :897-902. doi: 10.1053/j.ajkd.2005.07.044 [DOI] [PubMed] [Google Scholar]\n   2.Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. _J Am Soc Nephrol_. 2008. 19(1):135-140. doi: 10.1681/ASN.2007030308 [DOI] [PMC free a",
      "score": 0.4237686
    }
  ],
  "publishedAt": "2026-09-15T21:23:35.762385+00:00",
  "updatedAt": "2026-09-15T21:23:35.762385+00:00",
  "readingMinutes": 7,
  "slug": "vte-anticoagulation-duration"
}